115 related articles for article (PubMed ID: 28767374)
1. Continuous Petri Nets and microRNA Analysis in Melanoma.
Russo G; Pennisi M; Boscarino R; Pappalardo F
IEEE/ACM Trans Comput Biol Bioinform; 2018; 15(5):1492-1499. PubMed ID: 28767374
[TBL] [Abstract][Full Text] [Related]
2. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
[TBL] [Abstract][Full Text] [Related]
3. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
[TBL] [Abstract][Full Text] [Related]
4. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
Tembe V; Schramm SJ; Stark MS; Patrick E; Jayaswal V; Tang YH; Barbour A; Hayward NK; Thompson JF; Scolyer RA; Yang YH; Mann GJ
Pigment Cell Melanoma Res; 2015 May; 28(3):254-66. PubMed ID: 25490969
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
7. Integrated Genomics Identifies miR-32/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy.
Mishra PJ; Mishra PJ; Merlino G
PLoS One; 2016; 11(11):e0165102. PubMed ID: 27846237
[TBL] [Abstract][Full Text] [Related]
8. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.
Jiang W; Jia P; Hutchinson KE; Johnson DB; Sosman JA; Zhao Z
Oncotarget; 2015 Feb; 6(4):2496-508. PubMed ID: 25537510
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Exp Cell Res; 2015 Dec; 339(2):342-50. PubMed ID: 26384552
[TBL] [Abstract][Full Text] [Related]
11. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
Sand M; Skrygan M; Sand D; Georgas D; Gambichler T; Hahn SA; Altmeyer P; Bechara FG
Cell Tissue Res; 2013 Jan; 351(1):85-98. PubMed ID: 23111773
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Pereira TDSF; Brito JAR; Guimarães ALS; Gomes CC; de Lacerda JCT; de Castro WH; Coimbra RS; Diniz MG; Gomez RS
J Oral Pathol Med; 2018 Jan; 47(1):78-85. PubMed ID: 29032608
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.
Caramuta S; Egyházi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui WO
J Invest Dermatol; 2010 Aug; 130(8):2062-70. PubMed ID: 20357817
[TBL] [Abstract][Full Text] [Related]
14. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
15. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
16. The molecular pathology of cutaneous melanoma.
Bogenrieder T; Herlyn M
Cancer Biomark; 2010; 9(1-6):267-86. PubMed ID: 22112480
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-221 and -222 pathway controls melanoma progression.
Felicetti F; Errico MC; Segnalini P; Mattia G; Carè A
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1759-65. PubMed ID: 18983236
[TBL] [Abstract][Full Text] [Related]
18. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
19. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs in melanoma biology.
Kunz M
Adv Exp Med Biol; 2013; 774():103-20. PubMed ID: 23377970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
